Article
Targeting mTOR dependency in pancreatic cancer.
Gut - 1 Sept 2014
Morran Douglas C, Wu Jianmin, Jamieson Nigel B, Mrowinska Agata, Kalna Gabriela, Karim Saadia A, Au Amy Y M, Scarlett Christopher J, Chang David K, Pajak Malgorzata Z, Oien Karin A, McKay Colin J, Carter C Ross, Gillen Gerry, Champion Sue, Pimlott Sally L, Anderson Kurt I, Evans T R Jeffry, Grimmond Sean M, Biankin Andrew V, Sansom Owen J, Morton Jennifer P
Abstract excerpt
OBJECTIVE: Pancreatic cancer is a leading cause of cancer-related death in the Western world. Current chemotherapy regimens have modest survival benefit. Thus, novel, effective therapies are required for treatment of this disease. DESIGN: Activating KRAS mutation almost always drives pancreatic tumour initiation, however, deregulation of other potentially druggable pathways promotes tumour progression. PTEN loss...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.